We are grateful for the collaborative feedback from FDA on the Gemini program, which provides us a clear and expedient path forward for seeking approval of Gemini as a treatment for AKI,” said, James ...
SAN DIEGO, July 16, 2025--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation to ...
Revelation Biosciences shares jumped after the FDA agreed that a single Phase 2/3 study could support an application for its ...
SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...
SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained ...
Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ...
-Revelation to host conference call and webcast at 4:30 p.m. Eastern Time on January 11, 2022. The conference call can be accessed by dialing 877-815-0146 for domestic callers and 631-625-3219 for ...
PARIS, France—(UPDATED) A small, randomized trial may breathe new life into the concept of using a drug-coated balloon (DCB) instead of a stent in acute MI, particularly in younger patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results